These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34983918)

  • 1. Levosimendan and Continuous Outpatient Support With Inotropes in Patients With Advanced Heart Failure: A Single-Centre Descriptive Study.
    Yeung T; Dagan M; Lankaputhra M; Cieslik L; Warner V; Leet A; Hare JL; Bergin P; Taylor AJ; Kaye DM; Patel HC
    J Cardiovasc Pharmacol; 2022 Apr; 79(4):583-592. PubMed ID: 34983918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction.
    Cui X; Wang Z; Dong X; Cheng Z; Zhang L; Mu Y; Huang X; Li Y; Hong Y; Han Y
    J Cardiovasc Pharmacol; 2022 Jun; 79(6):781-790. PubMed ID: 35507915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
    Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive use of levosimendan in clinical practice: a case series.
    Wawrzyniak M; Migaj J; Straburzyńska-Migaj E; Dudek M; Kałużna-Oleksy M
    Cardiovasc J Afr; 2021 Nov-Dec 23; 32(6):339-342. PubMed ID: 33496720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.
    Bouchez S; Fedele F; Giannakoulas G; Gustafsson F; Harjola VP; Karason K; Kivikko M; von Lewinski D; Oliva F; Papp Z; Parissis J; Pollesello P; Pölzl G; Tschöpe C
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):617-624. PubMed ID: 30402660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis.
    Madeira M; Caetano F; Almeida I; Fernandes A; Reis L; Costa M; Gonçalves L
    Rev Port Cardiol; 2017 Sep; 36(9):619-625. PubMed ID: 28826934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
    Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.
    García-González MJ; de Mora-Martín M; López-Fernández S; López-Díaz J; Martínez-Sellés M; Romero-García J; Cordero M; Lara-Padrón A; Marrero-Rodríguez F; del Mar García-Saiz M; Aldea-Perona A;
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):573-9. PubMed ID: 23887741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of acute decompensated heart failure with levosimendan].
    Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
    Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
    García-González MJ; Aldea Perona A; Lara Padron A; Morales Rull JL; Martínez-Sellés M; de Mora Martin M; López Díaz J; López Fernandez S; Ortiz Oficialdegui P; Jiménez Sosa A
    ESC Heart Fail; 2021 Dec; 8(6):4820-4831. PubMed ID: 34716753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Levosimendan on cardiac function, size and strain in heart failure patients.
    Beitzke D; Gremmel F; Senn D; Laggner R; Kammerlander A; Wielandner A; Nolz R; Hülsmann M; Loewe C
    Int J Cardiovasc Imaging; 2021 Mar; 37(3):1063-1071. PubMed ID: 33103224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.